Loading…
ADARTREL is a brand name for Ropinirole. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: ADARTREL is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome.
Verbatim from this product's MHRA label. Tap a section to expand.
Oral use. Adults Individual dose titration against efficacy and tolerability is recommended. Ropinirole should be taken just before bedtime, however the dose can be taken up to 3 hours before retiring. Ropinirole may be taken with food, to improve gastrointestinal tolerance.
25 mg once daily (administered as above) for 2 days. 5 mg once daily for the remainder of week 1. Therapeutic regimen (week 2 onwards) Following treatment initiation, the daily dose should be increased until optimal therapeutic response is achieved.
The average dose in clinical trials, in patients with moderate to severe Restless Legs Syndrome, was 2 mg once a day. The dose may be increased to 1 mg once a day at week 2. 5 mg per week over the next two weeks to a dose of 2 mg once a day.
In some patients, to achieve optimal improvement, the dose may be increased gradually up to a maximum of 4 mg once a day. 5 mg each week to 3 mg once a day and then by 1 mg up to the maximum recommended dose of 4 mg once a day as shown in table 1.
Doses above 4 mg once daily have not been investigated in Restless Legs Syndrome patients. 5 3 4 * To achieve optimal improvement in some patients. 1). Patient response should be evaluated after 12 weeks treatment and the need for treatment continuation reconsidered.
If treatment is interrupted for more than a few days, it should be re-initiated by dose titration as noted above. When switching treatment from another dopamine agonist to ropinirole, the marketing authorisation holder’s guidance on discontinuation should be followed before initiating ropinirole.
4). Children and adolescents ADARTREL is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy. Elderly The clearance of ropinirole is decreased by approximately 15% in patients aged 65 years or above.
Although a dose adjustment is not required, ropinirole dose should be individually titrated, with careful monitoring of tolerability, to the optimal clinical response. Renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance between 30 and 50 mL/min).
25 mg once daily. Further dose escalations should be based on tolerability and efficacy. The recommended maximum dose of ADARTREL is 3 mg/day in patients receiving regular haemodialysis. 2). The use of ropinirole in patients with severe renal impairment (creatinine clearance less than 30 mL/min) without regular haemodialysis has not been studied.
Adverse drug reactions are listed below by system organ class and frequency. Frequencies from clinical trials are determined as excess incidence over placebo and are classed as very common (≥1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Use of ropinirole in Restless Legs Syndrome In Restless Legs Syndrome clinical trials, the most common adverse drug reaction was nausea (approximately 30% of patients).
Undesirable effects were normally mild to moderate and experienced at the start of therapy or on increase of dose and few patients withdrew from the clinical studies due to undesirable effects. 0% above the placebo rate or those reported uncommonly but known to be associated with ropinirole.
4) Respiratory, thoracic and mediastinal disorders Uncommon Hiccups Management of undesirable effects Dose reduction should be considered if patients experience significant undesirable effects. If the undesirable effect abates, gradual up-titration can be re-instituted.
Anti-nausea medicinal products that are not centrally active dopamine antagonists, such as domperidone, may be used, if required. Other experience with ropinirole Ropinirole is also indicated for the treatment of Parkinson's disease.
The adverse drug reactions reported in patients with Parkinson's disease on ropinirole monotherapy and adjunct therapy at doses up to 24 mg/day at an excess incidence over placebo are described below. Table 4 Adverse drug reactions reported in Parkinson's disease clinical trials at doses up to 24 mg/day Psychiatric disorders Common Hallucinations, confusion Uncommon Increased libido Nervous system disorders Very common Syncope, dyskinesia, somnolence Respiratory, thoracic and mediastinal disorders Uncommon Hiccups Gastrointestinal disorders Very common Nausea Common Vomiting, abdominal pain, heartburn General disorders and administration site conditions Common Oedema peripheral (including leg oedema Post marketing reports Hypersensitivity reactions (including urticaria, angioedema, rash, pruritus) Psychotic reactions (other than hallucinations) including delirium, delusion and paranoia have been reported.
g. caused by renal failure, iron deficiency anaemia or pregnancy). Paradoxical worsening of Restless Legs Syndrome symptoms described as augmentation (either earlier onset, increased intensity, or spread of symptoms to previously unaffected limbs), or early morning rebound (reoccurrence of symptoms in the early morning hours), have been observed during treatment with ropinirole.
8). 8) however, in Restless Legs Syndrome, this phenomenon is very rare. Nevertheless, patients must be informed of this phenomenon and advised to exercise caution while driving or operating machines during treatment with ropinirole.
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. A reduction of dosage or termination of therapy may be considered. Psychotic disorders Patients with major psychotic disorders should not be treated with dopamine agonists unless the potential benefits outweigh the risks.
Impulse control disorders Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Adartrel.
Dose reduction/tapered discontinuation should be considered if such symptoms develop. Mania Patients should be regularly monitored for the development of mania. Patients and carers should be made aware that symptoms of mania can occur with or without the symptoms of impulse control disorders in patients treated with ropinirole.
Dose reduction/tapered discontinuation should be considered if such symptoms develop. Neuroleptic malignant syndrome Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy.
1. Severe renal impairment (creatinine clearance < 30 mL/min) without regular haemodialysis. Severe hepatic impairment.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ropinirole in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Aggression (frequency not known): aggression has been associated with psychotic reactions as well as compulsive symptoms. Dopamine dysregulation syndrome (frequency not known). ). 4). Dopamine agonist withdrawal syndrome (frequency not known): including apathy, anxiety, depression, fatigue, sweating and pain.
4). Spontaneous penile erection (frequency not known). In Parkinson’s disease, ropinirole is associated with somnolence and has been associated uncommonly (≥ 1/1,000 to < 1/100) with excessive daytime somnolence and sudden sleep onset episodes, however, in Restless Legs Syndrome, this phenomenon is very rare (< 1/10,000).
Following ropinirole therapy, postural hypotension or hypotension has been reported uncommonly (≥ 1/1,000 to < 1/100), rarely severe. Very rare cases of hepatic reactions (< 1/10,000), mainly increase of liver enzymes, have been reported.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
2). Hypotension Due to the risk of hypotension, patients with severe cardiovascular disease (in particular coronary insufficiency) should be treated with caution. 8). 2). Limited data suggests that patients with impulse control disorders and those receiving high daily dose and/or high cumulative doses of dopamine agonists may be at higher risk for developing DAWS.
Withdrawal symptoms may include apathy, anxiety, depression, fatigue, sweating and pain and do not respond to levodopa. Prior to tapering off and discontinuing ropinirole, patients should be informed about potential withdrawal symptoms.
Patients should be closely monitored during tapering and discontinuation. In case of severe and/or persistent withdrawal symptoms, temporary re-administration of ropinirole at the lowest effective dose may be considered. Hallucinations Hallucinations are known as a side effect of treatment with dopamine agonists and levodopa.
Patients should be informed that hallucinations can occur. Patients with moderate hepatic impairment Ropinirole should be administered with caution to patients with moderate hepatic impairment. Undesirable effects should be closely monitored.
Excipients Lactose Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Sodium Each ADARTREL film coated tablet contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium free’.